Paper Details

  1. Home
  2. Paper Details

Memantine enhances autonomy in moderate to severe Alzheimer's disease.

Author: CochranJohn, DamierFlorence Delamarre, FrançoisClément, RiveBenoît, VercellettoMartine

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the benefits of memantine on functional disability in patients with moderately-severe to severe Alzheimer’s disease (AD). The study found that memantine enhanced autonomy in these patients, increasing the probability that they would remain autonomous, thereby delaying the transition to the dependent stage.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Alzheimer's disease (AD) is the leading cause of dementia and its course renders patients functionally disabled. Memantine is the first drug to demonstrate a clinical benefit in the treatment of patients with moderately-severe to severe AD. OBJECTIVES: Our objective was to illustrate th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/gps.1112

データ提供：米国国立医学図書館（NLM）

Memantine: A Potential Oasis in the Desert of Alzheimer's Disease

Alzheimer's disease (AD), the leading cause of dementia, casts a long shadow on the lives of millions worldwide. This research examines the impact of memantine, a medication for moderately severe to severe AD, on functional disability. The study evaluated 252 patients, assessing their Activities of Daily Living (ADL) capabilities using the ADCS-ADLsev scale. The results revealed that memantine treatment was associated with a significantly reduced risk of transitioning to a dependent stage, effectively enhancing autonomy in patients with AD. This finding sheds light on the potential of memantine to improve the quality of life for patients with AD.

Memantine: Empowering Autonomy in Alzheimer's Disease

This research underscores the importance of memantine in managing AD. Memantine demonstrates its potential to delay functional decline and improve the quality of life for patients with AD, allowing them to maintain their independence and participate in daily activities. The study highlights the potential of memantine to alleviate the burden of AD and create a more fulfilling experience for patients.

The Oasis of Memantine: A Beacon of Hope for Alzheimer's Patients

The benefits of memantine in managing AD are undeniable. It offers a path to increased autonomy and improved quality of life. While AD remains a formidable challenge, memantine provides a ray of hope in the vast desert of this debilitating disease. The potential of memantine to enhance the lives of patients with AD is a testament to the ongoing progress in medical research.

Dr. Camel's Conclusion

Memantine represents a valuable oasis in the vast and often unforgiving desert of Alzheimer's disease. Its ability to enhance autonomy in patients with AD is a significant step forward in addressing this devastating condition. Although the journey through AD remains challenging, memantine provides a glimmer of hope, allowing patients to navigate the desert with a greater sense of independence and dignity.

Date :
  1. Date Completed 2004-06-10
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15156547

DOI: Digital Object Identifier

10.1002/gps.1112

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.